ArticleNeuropsychiatric disease and treatment2025
Identification of Plasma Biomarkers in Untreated Schizophrenia Patients Using Untargeted Lipid Metabolomics.
Article in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Untargeted metabolomics reveals plasma metabolic dysregulation in schizophrenia.BMC psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Schizophrenia (SCZ) is a profound psychosomatic illness with an unidentified cause and no definitive biomarkers. This study sought to investigate plasma biomarkers linked to schizophrenia by untargeted metabolomics. Patients and Methods: A total of 50 medication-naïve SCZ patients and 25 healthy controls were eligible and participated in this study. Psychiatric symptomatology was evaluated employing the Positive and Negative Syndrome Scale. We quantified the concentration of lipid metabolites in plasma from all participants using untargeted metabolomics and classified metabolites that were significantly different between both groups. We subsequently assessed the diagnostic potential of metabolites on the basis of receiver operating characteristic curves and examined metabolites affiliated with psychotic symptomatology in SCZ patients. Results: Fourteen metabolites exhibited compelling disparities in schizophrenia patients relative to healthy controls. Eight metabolites, including methylphosphatidylcholine, acylcarnitine, sphingomyelin, and (O-acyl)-1-hydroxy fatty acids (38:4), could significantly distinguish between schizophrenia and healthy controls, with all their areas under the curve (AUC) exceeding 0.7. The peak area under the curve (CV-AUC) for AcCa(20:4) was 0.92 ± 0.03. In schizophrenia patients, negative symptoms exhibited a negative correlation with acylcarnitines, while cognitive symptoms had a substantial positive correlation with methylphosphatidylcholine and phosphatidylcholine. Conclusion: The findings reveal lipid metabolism dysregulation as a potential pathophysiological mechanism of schizophrenia. The identified metabolites, such as AcCa and phosphatidylcholine, serve as promising biomarkers for the diagnosis and symptom evaluation, suggesting their direct involvement in the disease's pathogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.